Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 18/20 | 0.74 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.45 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17899890 | 0.85 | SLC22A12 (1.00) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| SCHEMBL28386432 | 0.85 | SLC22A12 (0.53) | SLC22A12SLC22A6SLC22A11ABCG2TDP1 | |
| SCHEMBL17899864 | 0.80 | SLC22A12 (0.75) | SLC22A12TDP1KDM4EMAPT | |
| SCHEMBL14919143 | 0.79 | SLC22A12 (0.74) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| SCHEMBL9987685 | 0.76 | SLC22A12 (0.75) | SLC22A12SLC22A6SLC22A11ABCG2MAPT | |
| SCHEMBL28856524 | 0.76 | SLC22A12 (0.44) | SLC22A12SLC22A6SLC22A11ABCG2MAPT | |
| SCHEMBL18105441 | 0.75 | SLC22A12 (0.76) | SLC22A12SLC22A6SLC22A11 | |
| SCHEMBL18979023 | 0.74 | SLC22A12 (0.69) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| SCHEMBL18105429 | 0.74 | SLC22A12 (0.77) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| SCHEMBL19957696 | 0.74 | SLC22A12 (0.42) | SLC22A12SLC22A6SLC22A11ABCG2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3241822-B1 | URAT1 INHIBITOR | NIPPON CHEMIPHAR CO (JP) | 2021-03-24 | — | — | EP | claimed |
| US-10173990-B2 | URAT1 inhibitor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-01-08 | — | — | US | claimed |
| EP-3241822-A1 | URAT1 INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2017-11-08 | — | — | EP | claimed |
| US-20170290795-A1 | URAT1 INHIBITOR | J-PHARMA CO., LTD. (JP) | 2017-10-12 | — | — | US | claimed |
| EP-3241822-B1 | URAT1 INHIBITOR | NIPPON CHEMIPHAR CO (JP) | 2021-03-24 | — | — | EP | disclosed |
| US-10173990-B2 | URAT1 inhibitor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| US-10173990-B2 | URAT1 inhibitor | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-01-08 | — | — | US | disclosed |
| EP-3241822-A1 | URAT1 INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2017-11-08 | — | — | EP | disclosed |
| US-20170290795-A1 | URAT1 INHIBITOR | J-PHARMA CO., LTD. (JP) | 2017-10-12 | — | — | US | disclosed |
| US-20170290795-A1 | URAT1 INHIBITOR | J-PHARMA CO., LTD. (JP) | 2017-10-12 | — | — | US | disclosed |
| WO-2016108282-A1 | URAT1 INHIBITOR | 日本ケミファ株式会社 | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290795-A1 | URAT1 INHIBITOR | SLC10A1, XDH, URB2 | SLC22A12 512/4885SLC22A6 534/4885SLC22A11 263/4885 |
| US-10173990-B2 | URAT1 inhibitor | SLC10A1, XDH, URB2 | SLC22A12 500/4885SLC22A6 528/4885SLC22A11 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.